Recent patient studies surrounding Retatrutide , specifically the high-dose formulation branded as ZPHC, suggest a impressive impact on body mass decrease and associated metabolic conditions . Scientists anticipate that this combined acting , affecting both GLP-1 and GIP pathways , may represent